Document is current

Article History

Received: 14 October 2021

Revised: 4 February 2022

Accepted: 14 February 2022

First Online: 24 March 2022

Declarations

:

: Institutional Review Board approval was obtained: IRB approval#: 2015/2333/REK vest

: Written informed consent was obtained at primary diagnosis from all subjects in this retrospective study on prospectively collected data.

: The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

: The scientific guarantor of this publication is Professor Ingfrid S. Haldorsen.

: Øyvind Salvesen (one of the co-authors) is an expert in medical statistics.

: The presented study subjects are all included in the biobank for cervical cancer and clinical database at our institution, and overlapping cases have been presented in previous publications primarily focusing on clinicopathologic and molecular/genetic markers in cervical cancer. One previous small study (n = 53) have presented PET-CT parameters for overlapping cases included in this MRI study but with an entirely different aim and no overlapping results.Halle MK, Sødal M, Forsse D et al (2021) A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. Br J Cancer. 10.1038/s41416-021-01305-0Halle MK, Ojesina AI, Engerud H et al (2017) Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. Am J Obstet Gynecol 217:432.e431-432.e417Halle MK, Krakstad C, Engerud H, Bertelsen B, Salvesen HB (2014) Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. Pathol Res Pract 210:774-778Bollineni VR, Ytre-Hauge S, Gulati A et al (2018) The prognostic value of preoperative FDG-PET/CT metabolic parameters in cervical cancer patients. European Journal of Hybrid Imaging 2:24

: UnorderedList removed